As a general rule I’m not a big fan of buying banks in South America, but in the case of Banco Macro I’m willing to make an exception since our Rapid Profits Matrix likes it so much. Also, I am a big fan of Mauricio Macri, the current President of… Read More

A lot of money has been lost speculating on a turnaround in energy stocks during the past year. Trying to guess when the price of oil would finally bottom out, and how far it would rebound before leveling off, at times felt like a fool’s errand for industry analysts.  But… Read More

I’ll admit right off the bat that I don’t know much about fashion, especially when it comes to the type of women’s apparel and accessories sold by Michael Kors (KORS). But I do know an attractively priced stock when I see one, and apparently so do a lot of other… Read More

So long as the employment numbers don’t start unraveling, we may be able to avoid altogether the market meltdown many are expecting. Read More

We’re still a bit underwater on this trade, but that’s okay since we put a six-month shelf life on it to give it time to work out. Not helping is the inherently complex nature of what Myriad Genetics (MYGN) does, which is manufacturing and marketing predictive medical tests to determine… Read More

With the stock market becoming increasingly intolerant of companies that miss earnings or revenue expectations by even a little bit, this may be a particularly good time to look at our Smart Tech 50 portfolio table to identify attractive short sell candidates. To do that, I filtered that table by… Read More

Last week optionMonster reported that someone sold 9,150 January call options on Ziopharm Oncology (ZIOP) on Thursday with a strike price of $10, while 7,000 January call options with a strike price of $7 were purchased the same day. Presumably this spread contract was executed by the same buyer(s),… Read More

You can make money from the tech industry’s revolutions. Read More